Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.
You may also be interested in...
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
Blood pressure and C-reactive protein were modestly increased in the ACCELERATE trial of Lilly’s CETP inhibitor evacetrapib, but what exactly torpedoed the trial is still a mystery.